Pfizer-Wyeth refute charges of governance lapses in Indian merger
This article was originally published in Scrip
Executive Summary
Pfizer India has underscored that its proposed merger transaction with the Indian arm of Wyeth is unbiased to all shareholders and that the valuers used "generally accepted" valuation methodologies to recommend the fair equity share exchange ratio for the deal.